As the first therapeutically interchangeable Humira-referenced biosimilar Cyltezo may gain a distinct marketing advantage over competitors.
As First Therapeutically Interchangeable Humira-Referenced Biosimilar, Cyltezo Has A Marketing Advantage In U.S.
